<p>MannKind（纳斯达克：MNKD - 获取免费报告）于周三发布了季度财报。这家生物制药公司报告本季度每股收益为 0.03 美元，符合分析师的共识预期 0.03 美元，Zacks 报道。MannKind 的净利润率为 8.07%，股本回报率为负 17.74%。该公司本季度的收入为 7678 万美元，而分析师的预期为 7499 万美元。</p>
<h2>MannKind 价格表现</h2>
<p>周四交易时段，纳斯达克 MNKD 下跌 0.20 美元，报 5.28 美元。该公司股票成交量为 2,371,934 股，较其平均成交量 1,924,207 股有所增加。该公司的市值为 14.5 亿美元，市盈率为 75.37，贝塔值为 1.28。MannKind 的 52 周低点为 3.86 美元，52 周高点为 7.63 美元。该公司的 50 日移动平均线为 6.04 美元，200 日移动平均线为 6.28 美元。</p>
<h2>华尔街分析师观点</h2>
<p>几位分析师最近对该股票进行了评论。富国银行于 12 月 20 日星期五发布的研究报告中对 MannKind 的股票进行了覆盖，给予 “增持” 评级，并设定 9.00 美元的目标价。StockNews.com 在周三的研究报告中将 MannKind 的评级从 “持有” 上调至 “买入”。Wedbush 在周四的报告中重申了 “跑赢大盘” 的评级，并对 MannKind 的股票设定了 11.00 美元的目标价。最后，加拿大皇家银行在 12 月 19 日的研究报告中将 MannKind 的股票评级从 “行业表现” 上调至 “跑赢大盘”，并将其目标价从 7.00 美元上调至 10.00 美元。八位分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，平均目标价为 9.21 美元。</p>
<p><strong>查看我们关于 MannKind 的最新报告</strong></p>
<h2>关于 MannKind</h2>
<p>（获取免费报告）</p>
<p>MannKind Corporation 是一家生物制药公司，专注于开发和商业化用于内分泌和孤儿肺病的吸入治疗产品。它提供 Afrezza，一种用于改善糖尿病成人血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送设备，提供成人持续的皮下胰岛素输注。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 MannKind</li>
<li>关于 Markup 计算器</li>
<li>波动性回归：3 只股票缓解标准普尔 500 的波动</li>
<li>如何找到值得投资和交易的便士股票</li>
<li>2 个催化剂可能推动 NVIDIA 股票在今年上涨 30%</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>通用汽车的股票回购是否使股票对投资者可买？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p>
<h2>你现在应该投资 1000 美元在 MannKind 吗？</h2>
<p>在你考虑 MannKind 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 MannKind 并不在名单上。</p>
<p>虽然 MannKind 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

曼恩凯德生物医疗

<p>曼恩凯德生物医疗（NASDAQ:MNKD）公布了季度财报，每股收益为 0.03 美元，符合分析师的预期。该公司的净利润率为 8.07%，股本回报率为负 17.74%。本季度收入为 7678 万美元，超过了 7499 万美元的预测。分析师对曼恩凯德给予了 “买入” 评级，目标价格范围在 9.00 美元到 11.00 美元之间。该股票交易下跌至 5.28 美元，市值为 14.5 亿美元，市盈率为 75.37</p>

<p>MannKind (NASDAQ:MNKD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03, Zacks reports. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The business had revenue of $76.78 million for the quarter, compared to analysts' expectations of $74.99 million.</p>
<div class="lb-trans"><p>MannKind（纳斯达克：MNKD - 获取免费报告）于周三发布了季度财报。这家生物制药公司报告本季度每股收益为 0.03 美元，符合分析师的共识预期 0.03 美元，Zacks 报道。MannKind 的净利润率为 8.07%，股本回报率为负 17.74%。该公司本季度的收入为 7678 万美元，而分析师的预期为 7499 万美元。</p>
</div><h2>MannKind Price Performance</h2>
<div class="lb-trans"><h2>MannKind 价格表现</h2>
</div><p>NASDAQ MNKD traded down $0.20 during trading hours on Thursday, hitting $5.28. 2,371,934 shares of the company's stock traded hands, compared to its average volume of 1,924,207. The company has a market capitalization of $1.45 billion, a PE ratio of 75.37 and a beta of 1.28. MannKind has a 52-week low of $3.86 and a 52-week high of $7.63. The firm's 50-day moving average is $6.04 and its 200-day moving average is $6.28.</p>
<div class="lb-trans"><p>周四交易时段，纳斯达克 MNKD 下跌 0.20 美元，报 5.28 美元。该公司股票成交量为 2,371,934 股，较其平均成交量 1,924,207 股有所增加。该公司的市值为 14.5 亿美元，市盈率为 75.37，贝塔值为 1.28。MannKind 的 52 周低点为 3.86 美元，52 周高点为 7.63 美元。该公司的 50 日移动平均线为 6.04 美元，200 日移动平均线为 6.28 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several analysts recently commented on the stock. Wells Fargo &amp; Company initiated coverage on shares of MannKind in a research report on Friday, December 20th. They set an &#34;overweight&#34; rating and a $9.00 price target on the stock. StockNews.com upgraded MannKind from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday. Wedbush reissued an &#34;outperform&#34; rating and issued a $11.00 price target on shares of MannKind in a report on Thursday. Finally, Royal Bank of Canada upgraded shares of MannKind from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and upped their price target for the stock from $7.00 to $10.00 in a research report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and an average price target of $9.21.</p>
<div class="lb-trans"><p>几位分析师最近对该股票进行了评论。富国银行于 12 月 20 日星期五发布的研究报告中对 MannKind 的股票进行了覆盖，给予 “增持” 评级，并设定 9.00 美元的目标价。StockNews.com 在周三的研究报告中将 MannKind 的评级从 “持有” 上调至 “买入”。Wedbush 在周四的报告中重申了 “跑赢大盘” 的评级，并对 MannKind 的股票设定了 11.00 美元的目标价。最后，加拿大皇家银行在 12 月 19 日的研究报告中将 MannKind 的股票评级从 “行业表现” 上调至 “跑赢大盘”，并将其目标价从 7.00 美元上调至 10.00 美元。八位分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，平均目标价为 9.21 美元。</p>
</div><p><strong>Check Out Our Latest Report on MannKind</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MannKind 的最新报告</strong></p>
</div><h2>About MannKind</h2>
<div class="lb-trans"><h2>关于 MannKind</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物制药公司，专注于开发和商业化用于内分泌和孤儿肺病的吸入治疗产品。它提供 Afrezza，一种用于改善糖尿病成人血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送设备，提供成人持续的皮下胰岛素输注。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MannKind</li>
<li>About the Markup Calculator</li>
<li>Volatility Is Back: 3 Stocks To Cushion the S&amp;P 500's Swings</li>
<li>How to find penny stocks to invest and trade</li>
<li>2 Catalysts That Could Push NVIDIA Stock Up 30% This Year</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Do GM Stock Buybacks Make the Stock Buyable For Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 MannKind</li>
<li>关于 Markup 计算器</li>
<li>波动性回归：3 只股票缓解标准普尔 500 的波动</li>
<li>如何找到值得投资和交易的便士股票</li>
<li>2 个催化剂可能推动 NVIDIA 股票在今年上涨 30%</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>通用汽车的股票回购是否使股票对投资者可买？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MNKD"/></p>
<h2>Should You Invest $1,000 in MannKind Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 MannKind 吗？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MannKind 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 MannKind 并不在名单上。</p>
</div><p>While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MannKind 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

曼恩凯德生物医疗（NASDAQ:MNKD）公布财报结果